Turn Therapeutics (TTRX) Total Debt (2025 - 2026)

Turn Therapeutics (TTRX) recorded quarterly Total Debt of $8.7 million in Q1 2026, up 187.41% quarter-over-quarter from $3.0 million in Q4 2025.

Turn Therapeutics (TTRX) Total Debt (2025 - 2026) Analysis & Trends

Turn Therapeutics' Total Debt history runs 2 years deep, the most recent figure standing at $8.7 million for Q1 2026.

  • In Q1 2026, Total Debt changed N/A year-over-year to $8.7 million; the TTM figure through Mar 2026 stood at $8.7 million (changed N/A YoY), while the FY2025 annual figure was $3.0 million, changed N/A from the prior year.
  • Total Debt was $8.7 million for Q1 2026 at Turn Therapeutics, up from $3.0 million in the prior quarter.
  • In the past five years, Total Debt ranged from a high of $8.7 million in Q1 2026 to a low of $3.0 million in Q4 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Debt (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn - -
2 Belite Bio 58,560.00 Bn 58,560.00 Bn - -
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn - -
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn 319.10 Mn
5 Evaxion A 1,334.43 Bn 1,334.42 Bn - -
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn - -
7 Psyence Biomedical 212.16 Bn 212.16 Bn - -
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn -
9 Abivax 91.96 Bn 91.96 Bn - -
10 Turn Therapeutics 175.38 Mn 175.38 Mn - 8.70 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 8.70 Mn
Dec 31, 2025 3.03 Mn